Search

TRICALS is a network of top ALS research centres across Europe

This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.

Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound 'AMX0035'.

The CARDINALS clinical research study is evaluating a study drug (Utreloxastat) to see if it can help slow ALS symptoms.

Verge Genomics is conducting a phase 1b trial to evaluate the safety, tolerability, and potential efficacy of VRG50635.

In this study we investigate the safety, tolerability, pharmacodynamics markers and pharmacokinetics of AP-101 in patients with ALS.

This trial evaluates the efficacy and safety and of an investigational drug for pre-symptomatic carriers of the SOD1 gene.

This study investigates the safety & efficacy of the study drug ‘ION363’ for the treatment of ALS caused by mutations in the FUS gene.

Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of FNP122 for people with ALS.

In this research we investigate the safety of the new drug prosetin for the treatment of ALS.

The Lighthouse 2 study is a phase 3 clinical trial in which we will investigate the efficacy of the drug Triumeq.

The MAGNET lithium trial studies the efficacy of lithium carbonate in ALS patients positive for the homozygous UNC13A mutation.